Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Fatigue is one of the most common symptoms experienced by those living with CLL and SLL, and it is also commonly overlooked,underreported, and undertreated.
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of
a type of white blood cell called B-lymphocytes.
Autoimmune hemolytic anemia (AIHA) is the most common autoimmune condition associated with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Tumor lysis syndrome is a rare condition that can happen due to the rapid death of cancer cells. When the cancer cells are killed, the debris from inside the cells enters the bloodstream.
Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).
As a caregiver to my husband who currently has three cancers, I can truly say that the most significant help I have gotten has been from CLL Society.
A newly published paper in JAMA Oncology found that among cancer patients with suspected ibrutinib-related cardiotoxic effects, the presence of heart muscle injury and scarring is high, and this is associated with an increased risk of developing future cardiovascular adverse events.
The study looked at 5-year overall survival (OS) in treatment naïve CLL (chronic lymphocytic leukemia) patients who were unfit or > 65 years old compared to an age and gender-matched general population (AGMGP) without CLL.
No new concerns or safety signals were found in old and frail chronic lymphocytic leukemia (CLL) patients treated with acalabrutinib.
One click to our most popular content.
